18:58 , May 9, 2018 |  BC Innovations  |  Translation in Brief

Dissecting rare gliomas

In an April Science study, researchers from Massachusetts General Hospital and Harvard Medical School identified a subpopulation of malignant cells driving disease progression in rare pediatric gliomas with mutated histone H3 K27M using single-cell RNA...
19:17 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Mouse studies suggest inhibiting BMI1 could help treat castration-resistant prostate cancer (CRPC). In a mouse model of CRPC, a tool compound BMI1 inhibitor decreased tumor growth compared with vehicle. Also in the...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
00:52 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer Cell culture and mouse studies suggest BMI1 inhibitors could help treat cisplatin-resistant head and neck cancers. Primary human squamous cell carcinoma of the head and neck (SCCHN) stem cells had higher...
17:59 , Feb 15, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on four genomic loci could help predict the risk of prostate cancer. Genome-wide association studies in 40,925 healthy volunteers and 5,006 prostate cancer patients identified associations between levels of the prostate cancer marker...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BMI1 polycomb ring finger oncogene (BMI1); CCAAT enhancer binding protein α (CEBPA)

Cancer INDICATION: Non-small cell lung cancer (NSCLC) Patient sample, cell culture and mouse studies suggest inhibiting BMI1 could help treat NSCLC patients who have low tumor levels of CEBPA. In NSCLC patients with low tumor levels...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

PTC596: Phase I started

PTC began an open-label, dose-escalation, U.S. Phase I trial evaluating twice-weekly oral PTC596, starting at 0.65 mg/kg, in about 60 patients. PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J.   Product: PTC596   Business: Cancer   Molecular target:...
08:00 , Mar 6, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Induced pluripotent stem (iPS) cell-derived immortalized megakaryocyte progenitor cell lines as a self-renewing source for human platelets In vitro...
08:00 , Jan 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colon cancer BMI1 polycomb ring finger oncogene (BMI1) In vitro and mouse studies suggest inhibiting BMI1 expression...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

PTC, The Wellcome Trust cancer news

PTC received a $2.3 million installment of a $5.4 million grant awarded in June 2010 from the Wellcome Trust's Seeding Drug Discovery initiative to develop therapeutics that target BMI1 polycomb ring finger oncogene (BMI1)....